Euronext Paris

EQS-News: Abivax appoints Ana Sharma as Vice President, Global Head of Quality

Retrieved on: 
Wednesday, February 7, 2024

Abivax appoints Ana Sharma as Vice President, Global Head of Quality

Key Points: 
  • Abivax appoints Ana Sharma as Vice President, Global Head of Quality
    The issuer is solely responsible for the content of this announcement.
  • Abivax appoints Ana Sharma as Vice President, Global Head of Quality
    PARIS, France, February 7, 2024, 8:30 a.m. CET – Abivax SA (Euronext Paris and Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, today announced the appointment of Ana Sharma as Vice President, Global Head of Quality.
  • Ms. Sharma brings over 20 years of experience in the biopharmaceutical industry and has a strong track record in quality and GxP compliance.
  • If approved, it would be available to many patients who are in need of safe and long-term efficacious therapeutic options for chronic inflammatory diseases.”
    Ana Sharma joined Abivax from Takeda, where she held the position of Vice President, Global Head of Research and Development Clinical Quality Assurance.

Abivax appoints Ana Sharma as Vice President, Global Head of Quality

Retrieved on: 
Wednesday, February 7, 2024

Abivax appoints Ana Sharma as Vice President, Global Head of Quality

Key Points: 
  • Abivax appoints Ana Sharma as Vice President, Global Head of Quality
    PARIS, France, February 7, 2024, 8:30 a.m. CET – Abivax SA (Euronext Paris and Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, today announced the appointment of Ana Sharma as Vice President, Global Head of Quality.
  • Ms. Sharma brings over 20 years of experience in the biopharmaceutical industry and has a strong track record in quality and GxP compliance.
  • Marc de Garidel, Chief Executive Officer of Abivax, says: “I am glad Ana joins our team with her extensive experience in research and development quality assurance in the biopharmaceutical sector.
  • If approved, it would be available to many patients who are in need of safe and long-term efficacious therapeutic options for chronic inflammatory diseases.”
    Ana Sharma joined Abivax from Takeda, where she held the position of Vice President, Global Head of Research and Development Clinical Quality Assurance.

Quadient’s Financial Automation Cloud Offerings Named as Recommended Solutions by Sage

Retrieved on: 
Tuesday, February 6, 2024

Sage has given Quadient a Tech Partner Plus status, recommending Quadient AR and Quadient AP for Sage Intacct customers and partners seeking to automate and optimize the order-to-cash and procure-to-pay processes.

Key Points: 
  • Sage has given Quadient a Tech Partner Plus status, recommending Quadient AR and Quadient AP for Sage Intacct customers and partners seeking to automate and optimize the order-to-cash and procure-to-pay processes.
  • Sage Intacct helps organizations thrive in today’s digital world with proven cloud native solutions across accounting, planning, analytics and payroll.
  • The powerful cloud platform offers deep multi-dimensional insight and AI-powered automation which enables organizational agility, leading to increased profitability and enhanced customer satisfaction.
  • “Sage has a rich history with Quadient, and we are excited to deepen our relationship and integration with the company.

Assystem and Dassault Systèmes Partner to Accelerate the Development of Advanced Modular Reactors

Retrieved on: 
Tuesday, February 6, 2024

Dassault Systèmes (Euronext Paris: FR0014003TT8, DSY.PA) and Assystem, an international engineering, digital services and project management company, today announced their partnership to accelerate the development of advanced modular nuclear reactors that can produce efficient, safe and reliable energy.

Key Points: 
  • Dassault Systèmes (Euronext Paris: FR0014003TT8, DSY.PA) and Assystem, an international engineering, digital services and project management company, today announced their partnership to accelerate the development of advanced modular nuclear reactors that can produce efficient, safe and reliable energy.
  • Dassault Systèmes and Assystem will implement Dassault Systèmes’ 3DEXPERIENCE platform and Assystem’s system engineering and project management services and support for customers.
  • “The complementarity between Assystem and Dassault Systèmes makes sense for the nuclear sector.
  • “Our 3DEXPERIENCE platform has proven its versatility in responding to the unique needs of 12 industries served by Dassault Systèmes.

EQS-News: Abivax announces update to obefazimod Phase 2b clinical development program in moderately to severely active Crohn’s disease

Retrieved on: 
Monday, February 5, 2024

Sheldon Sloan, MD, M Bioethics, CMO of Abivax, says: “The IND clearance by the FDA allows Abivax to move forward with the development of obefazimod for the treatment of Crohn’s disease.

Key Points: 
  • Sheldon Sloan, MD, M Bioethics, CMO of Abivax, says: “The IND clearance by the FDA allows Abivax to move forward with the development of obefazimod for the treatment of Crohn’s disease.
  • We are excited to begin the obefazimod CD program, which has the potential to provide a meaningful benefit to patients in a therapeutic area with a high unmet medical need.”
    The obefazimod Phase 2b clinical trial in moderately to severely active CD is a double-blind placebo-controlled trial, evaluating three obefazimod doses.
  • The revised trial design takes into account FDA recommendations provided in the frame of an initial Phase 2a IND submission.
  • These adjustments to the obefazimod CD clinical program are not expected to have an impact on the overall program budget and projected supplemental New Drug Application (sNDA) submission timeline.

Valneva Announces Sale of Priority Review Voucher for $103 Million

Retrieved on: 
Monday, February 5, 2024

Saint-Herblain (France), February 5, 2024 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced it sold the Priority Review Voucher (PRV) it received from the U.S. Food and Drug Administration (FDA) for $103 million (€95 million).

Key Points: 
  • Saint-Herblain (France), February 5, 2024 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced it sold the Priority Review Voucher (PRV) it received from the U.S. Food and Drug Administration (FDA) for $103 million (€95 million).
  • With this approval, IXCHIQ® became the world’s first licensed chikungunya vaccine available to address this unmet medical need.
  • As shown with the recent approval of our chikungunya vaccine, we remain committed to growing our portfolio of vaccines addressing unmet medical needs which have the potential to transform people’s lives.”
    Under the tropical Disease Priority Review Voucher Program, FDA awards priority review vouchers to sponsors of tropical disease product applications that meet certain criteria.
  • PRVs can be redeemed to receive priority review of a subsequent marketing application for a different product, sold or transferred.

Abivax announces update to obefazimod Phase 2b clinical development program in moderately to severely active Crohn’s disease

Retrieved on: 
Friday, February 2, 2024

Sheldon Sloan, MD, M Bioethics, CMO of Abivax, says: “The IND clearance by the FDA allows Abivax to move forward with the development of obefazimod for the treatment of Crohn’s disease.

Key Points: 
  • Sheldon Sloan, MD, M Bioethics, CMO of Abivax, says: “The IND clearance by the FDA allows Abivax to move forward with the development of obefazimod for the treatment of Crohn’s disease.
  • We are excited to begin the obefazimod CD program, which has the potential to provide a meaningful benefit to patients in a therapeutic area with a high unmet medical need.”
    The obefazimod Phase 2b clinical trial in moderately to severely active CD is a double-blind placebo-controlled trial, evaluating three obefazimod doses.
  • The revised trial design takes into account FDA recommendations provided in the frame of an initial Phase 2a IND submission.
  • These adjustments to the obefazimod CD clinical program are not expected to have an impact on the overall program budget and projected supplemental New Drug Application (sNDA) submission timeline.

Quadient extends its footprint in Europe, welcoming 30,000 new customers with the acquisition of Frama

Retrieved on: 
Thursday, February 1, 2024

Frama has been a trusted and strategic partner of Quadient for over ten years, selling Quadient’s folder inserters, and more recently its line of mailing machines, both sold under the Frama brand.

Key Points: 
  • Frama has been a trusted and strategic partner of Quadient for over ten years, selling Quadient’s folder inserters, and more recently its line of mailing machines, both sold under the Frama brand.
  • “I am very pleased to welcome the Frama customers, partners and employees to the Quadient community,” comments Geoffrey Godet, CEO of Quadient.
  • “For over a decade, Frama has been a strong partner, reselling Quadient solutions and helping customers transition their business communications to digital.
  • We are excited to offer the Frama customer base the opportunity to leverage Quadient’s software and parcel locker solutions.

Sodexo confirms the Pluxee spin-off following its Shareholders Meeting of January 30, 2024

Retrieved on: 
Tuesday, January 30, 2024

With the approval of the distribution in kind of Pluxee shares to Sodexo shareholders during this Shareholders Meeting, Sodexo is making a major strategic step forward, and confirms the spin-off and listing of Pluxee on February 1, 2024.

Key Points: 
  • With the approval of the distribution in kind of Pluxee shares to Sodexo shareholders during this Shareholders Meeting, Sodexo is making a major strategic step forward, and confirms the spin-off and listing of Pluxee on February 1, 2024.
  • Sodexo held a Shareholders Meeting on Tuesday, January 30, 2024, chaired by Sophie Bellon, Chairwoman of the Board of Directors and Chief Executive Officer of Sodexo.
  • Delivery of the Pluxee shares to shareholders is scheduled for February 5, 2024.
  • The Shareholders Meeting was broadcast live and the replay will be available very soon, in French and English, as well as the detailed results of the votes, on sodexo.com, in the "Investors – Shareholders – Shareholders Meetings" section.

Verimatrix and Amazon Web Services Collaborate to Further Increase Speed and Reliability for OTT Content Security

Retrieved on: 
Thursday, February 1, 2024

Verimatrix , (Euronext Paris: VMX), the leader in powering the modern connected world with people-centered security, today announced collaboration with Amazon Web Services (AWS) to further bolster scalability, availability and ease of use for its Streamkeeper Multi-DRM cloud-based OTT content security platform.

Key Points: 
  • Verimatrix , (Euronext Paris: VMX), the leader in powering the modern connected world with people-centered security, today announced collaboration with Amazon Web Services (AWS) to further bolster scalability, availability and ease of use for its Streamkeeper Multi-DRM cloud-based OTT content security platform.
  • Streamkeeper Multi-DRM, a multi-tenant platform deployed on the AWS cloud, is compatible with AWS SPEKE to work seamlessly with AWS Media Services.
  • It leverages AWS Global Accelerator and AWS Route 53 to allow lightning-speed content consumption, provide top-notch reliability, and consistently autoscale for peak events.
  • Additionally, AWS Shield, AWS WAF and AWS Key Management Service (KMS) ensure Streamkeeper Multi-DRM services enjoy powerful protections against malicious attacks.